Investors & Media

Stock Info
NASDAQBCLI
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

Brainstorm’s Alzheimer’s Key Opinion Leader Event

Brainstorm’s July 8, 2020 Key Opinion Leader (KOL) Webinar on the Company's Alzheimer's Disease (AD) Clinical Program.

Corresponding Presentation

Recent News
Jan 4, 2022

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D. MHSc, President and...

Dec 27, 2021

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing extension of NurOwn® for...

Dec 13, 2021

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of Phase 3 clinical data...

View All

Events
Monday, January 17, 2022 - Tuesday, January 18, 2022

View All

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds